ライフサイエンスコーパス: purpura

1 anchored to ECs (thrombotic thrombocytopenic purpura).

2 mic syndrome and thrombotic thrombocytopenic purpura.

3 thogenesis and treatment of Henoch-Schonlein purpura.

4 lter the natural history of Henoch-Schonlein purpura.

5 sis of Kawasaki disease and Henoch-Schonlein purpura.

6 otease, leads to thrombotic thrombocytopenic purpura.

7 hogenesis of chronic immune thrombocytopenic purpura.

8 n bleeding disorder, immune thrombocytopenic purpura.

9 d chronic refractory immune thrombocytopenic purpura.

10 tions for refractory immune thrombocytopenic purpura.

11 atients with chronic immune thrombocytopenic purpura.

12 atients with chronic immune thrombocytopenic purpura.

13 protease, causes thrombotic thrombocytopenic purpura.

14 treatment of chronic immune thrombocytopenic purpura.

15 egnant patients with immune thrombocytopenic purpura.

16 ficient to cause thrombotic thrombocytopenic purpura.

17 plasma leads to thrombotic thrombocytopenic purpura.

18 pproach to childhood immune thrombocytopenic purpura.

19 in the treatment of immune thrombocytopenic purpura.

20 le in idiopathic thrombotic thrombocytopenic purpura.

21 ma-enhanced model of immune thrombocytopenic purpura.

22 hese infections, not immune thrombocytopenic purpura.

23 reating acquired thrombotic thrombocytopenic purpura.

24 mbocytopenia and autoimmune thrombocytopenic purpura.

25 hesion may cause thrombotic thrombocytopenic purpura.

26 lapsing cases of thrombotic thrombocytopenic purpura.

27 ers from that of thrombotic thrombocytopenic purpura.

28 lapsing acquired thrombotic thrombocytopenic purpura.

29 oimmune thrombocytopenia and posttransfusion purpura.

30 glomerulonephritis, and/or Henoch Schoenlein purpura.

31 lethal syndrome, thrombotic thrombocytopenic purpura.

32 t long-term consequences of Henoch-Schonlein purpura.

33 vasculitides of childhood: Henoch-Schonlein purpura.

34 uired idiopathic thrombotic thrombocytopenic purpura.

35 with idiopathic thrombotic thrombocytopenic purpura.

36 nt management of thrombotic thrombocytopenic purpura.

37 of patients afflicted with Henoch-Schonlein purpura.

38 ctors in the development of Henoch-Schonlein purpura.

39 pathic disorder, thrombotic thrombocytopenic purpura.

40 ADAMTS13 causes thrombotic thrombocytopenic purpura.

41 met criteria for thrombotic thrombocytopenic purpura.

42 which may cause thrombotic thrombocytopenic purpura.

43 luding Kawasaki disease and Henoch-Schonlein purpura.

44 distinguishable from immune thrombocytopenic purpura.

45 ce in a model of thrombotic thrombocytopenic purpura.

46 MTS13 that cause thrombotic thrombocytopenic purpura.

47 utoantibodies in thrombotic thrombocytopenic purpura.

48 y experienced in thrombotic thrombocytopenic purpura.

49 eficiency causes thrombotic thrombocytopenic purpura.

50 e sclerosis, and idiopathic thrombocytopenic purpura.

51 ristic for acute thrombotic thrombocytopenic purpura.

52 called acquired thrombotic thrombocytopenic purpura.

53 atients with chronic immune thrombocytopenic purpura.

54 on nucleosome levels in children with septic purpura.

55 es, particularly thrombotic thrombocytopenic purpura.

56 ity and the pathogenesis of Henoch-Schonlein purpura.

57 kin manifestations, including 39 (8.0%) with purpura, 13 (2.7%) with Osler nodes, 8 (1.6%) with Janew

58 spherocytosis (111), immune thrombocytopenic purpura (36), sickle cell disease (SCD) (51), and other

59 Baseline manifestations were purpura (75%), peripheral neuropathy (52%), arthralgia o

60 Thrombotic thrombocytopenic purpura, a clinical syndrome characterized by thrombocyt

61 tinction between thrombotic thrombocytopenic purpura, a disease characterized by a lack of ADAMTS13 a

62 cells and causes thrombotic thrombocytopenic purpura, a disease with similarities to D+HUS, in Adamts

63 e pathophysiology of immune thrombocytopenic purpura, a disorder in which autoantibodies against cell

64 uring therapy of thrombotic thrombocytopenic purpura, a subtype of TMAs often associated with severe

65 Besides studies of Henoch-Schonlein purpura, advances in pediatric vasculitis are few as a r

66 wo patients with thrombotic thrombocytopenic purpura and a healthy person.

67 current research in immune thrombocytopenic purpura and a preview of agents in development are provi

68 hird, studies on thrombotic thrombocytopenic purpura and ADAMTS13-knockout mice suggest that ADAMTS13

69 hrombocytopenia, thrombotic thrombocytopenia purpura and antiphospholipid syndrome.

70 ages 39-50 years who presented with retiform purpura and cutaneous necrosis.

71 (TMA), including thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome, have been reporte

72 nia in patients with immune thrombocytopenia purpura and hepatitis C without the development of an im

73 ed several polymorphisms in Henoch-Schonlein purpura and Kawasaki Disease as well as the association

74 atric vasculitis syndromes, Henoch-Schonlein purpura and Kawasaki disease.

75 pathogenesis of thrombotic thrombocytopenic purpura and other arterial thromboses associated with co

76 mbotic agent for thrombotic thrombocytopenic purpura and other thrombotic conditions.

77 or patients with idiopathic thrombocytopenic purpura and persistent severe thrombocytopenia after spl

78 associated with thrombotic thrombocytopenic purpura and sepsis was revealed by the inverse relations

79 om patients with thrombotic thrombocytopenic purpura and sequence alignment of the ADAMTS13 spacer do

80 ents with refractory immune thrombocytopenic purpura and severe thrombocytopenia with bleeding only i

81 thritis, cancer, thrombotic thrombocytopenic purpura and the Ehlers-Danlos type VIIC and Weill-Marche

82 distinction from thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome.

83 Mutations from thrombotic thrombocytopenic purpura and von Willebrand disease provide clues for the

84 EFV in Behcet's disease and Henoch-Schonlein purpura, and A1AT in Wegener's granulomatosis.

85 agnosed with primary immune thrombocytopenic purpura, and are not associated with distinctive clinica

86 tations of IE (Osler nodes, Janeway lesions, purpura, and conjunctival hemorrhages).

87 er pylori-associated immune thrombocytopenic purpura, and Ghevaert et al. describe a specially design

88 symptoms of common disorders, such as senile purpura, and have subtle histologic findings.

89 A nephropathy, Tn syndrome, Henoch-Schonlein purpura, and malignant transformation, all of which are

90 case of possible thrombotic thrombocytopenia purpura, and recovered after therapy with plasmapheresis

91 SERVATIONS A woman in her 30s presented with purpura annularis telangiectodes of Majocchi on the lowe

92 herited and acquired immune thrombocytopenic purpura as well as clinical practice on the initial diag

93 The severe ecchymoses and purpura associated with meningococcal sepsis are usually

94 heumatoid arthritis, immune thrombocytopenic purpura, autoimmune hemolytic anemia, systemic lupus ery

95 ble diagnosis of thrombotic thrombocytopenic purpura between Jan 8, 2004, and Dec 6, 2015, were inclu

96 rtant therapy in thrombotic thrombocytopenic purpura, but clinical data for adjunctive therapies, suc

97 ibility and pathogenesis of Henoch-Schonlein purpura, but there are still significant gaps in our kno

98 actice guideline for immune thrombocytopenic purpura, but treatment recommendations of necessity were

99 uremic syndrome, thrombotic thrombocytopenic purpura, C3GN, and dense deposit disease, which share ph

100 reported for 2.9% of immune thrombocytopenic purpura cases treated with rituximab, but they could not

101 m a rare form of idiopathic thrombocytopenic purpura caused by a GPVI-specific autoantibody that medi

102 lupus erythematosus, immune thrombocytopenic purpura, chronic cold agglutinin disease, IgM-mediated n

103 me patients with thrombotic thrombocytopenic purpura; conversely such deficiency is consistently abse

104 with congenital thrombotic thrombocytopenic purpura (cTTP) who cannot cleave VWF multimers because o

105 idate the manifestations of Henoch-Schonlein purpura, determine appropriate treatment of the disease,

106 ng from acquired thrombotic thrombocytopenic purpura develop autoantibodies directed toward the plasm

107 esis of clinical thrombotic thrombocytopenic purpura, especially in relation to ADAMTS13.

108 Thrombotic thrombocytopenic purpura exemplifies how von Willebrand factor can be res

109 is and management of immune thrombocytopenic purpura focused entirely on primary disease, and seconda

110 ears of age, had idiopathic thrombocytopenic purpura for more than 3 months, had a previous splenecto

111 Purpura fulminans in adults is a rare but devastating di

112 Homozygous deficiency usually manifests as purpura fulminans in infancy and is often fatal.

113 Skin biopsies in purpura fulminans lesions revealed thrombosis and extens

114 Purpura fulminans was a frequent complication, developin

115 Twenty patients with severe sepsis and purpura fulminans were recruited for blood sampling, and

116 d severe deficiency associated with neonatal purpura fulminans.

117 eficiency of protein C, who develop neonatal purpura fulminans.

118 botic local imbalance are characteristics of purpura fulminans.

119 s showed that these lesions were specific to purpura fulminans.

120 ggers the vascular damages that characterize purpura fulminans.

121 Patients with purpura had larger cardiac vegetations (18.1 vs 13.7 mm,

122 immune globulin for immune thrombocytopenic purpura has been reported with an estimated incidence of

123 most effective treatment of Henoch-Schonlein purpura has begun to emerge.

124 eatment landscape of immune thrombocytopenic purpura has the potential for dramatic change in the nea

125 Studies of Henoch-Schonlein purpura have focused on pathogenesis and outcome.

126 gy of idiopathic thrombotic thrombocytopenic purpura have provided the rationale for immune-based tre

127 Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is an inclus

128 of patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is difficult

129 inine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is thought t

130 distinction from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome difficult or impossibl

131 of occurrence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy and (

132 Case series of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from 1964 to 2002 were

133 r development of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome is near term and durin

134 Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome occurs more commonly i

135 Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome was associated with qu

136 ital or familial thrombotic thrombocytopenic purpura-hemolytic uremic syndrome who were initially dia

137 or occurrence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

138 ecently reported thrombotic thrombocytopenia purpura/hemolytic uremic syndrome (TTP/HUS) case involve

139 er TMAs, such as thrombotic thrombocytopenic purpura; however, novel bioassays are being developed.

140 Although Henoch-Schonlein purpura (HSP) can occur at any age from infancy to adult

141 Henoch Schonlein Purpura (HSP) is the commonest systemic vasculitis of ch

142 children and chronic immune thrombocytopenic purpura in adults.

143 of acute and chronic immune thrombocytopenic purpura in children and chronic immune thrombocytopenic

144 sis and treatment of immune thrombocytopenic purpura in children continue to evolve.

145 immune thrombocytopenia and post-transfusion purpura in individuals with the alphaII(B)betaIII 33:Pro

146 esent guidelines for immune thrombocytopenic purpura in pregnancy based on evidence-based data from p

147 associated with thrombotic thrombocytopenic purpura, in which life-threatening episodes of microangi

148 ritish guidelines on immune thrombocytopenic purpura incidence, prevalence, and natural history, with

149 pid syndrome and thrombotic thrombocytopenic purpura, include immunosuppression and systemic anticoag

150 ar changes occurring during Henoch-Schonlein purpura, including cytokines, and endothelial and nitric

151 cute episodes of thrombotic thrombocytopenic purpura, independent of ADAMTS13 activity.

152 ronic refractory idiopathic thrombocytopenic purpura is a dilemma because many patients have minimal

153 The diagnosis of immune thrombocytopenic purpura is a process of elimination of other sources of

154 Thrombotic thrombocytopenic purpura is a rare complication of thienopyridine treatme

155 Thrombotic thrombocytopenic purpura is associated with acquired or congenital defici

156 acquired form of thrombotic thrombocytopenic purpura is associated with inhibitory autoantibodies aga

157 Thrombotic thrombocytopenic purpura is caused by congenital or acquired deficiency o

158 microangiopathy, thrombotic thrombocytopenic purpura is distinguished by a severe deficiency in the A

159 vity in acquired thrombotic thrombocytopenic purpura is due to an autoantibody inhibitor of the von W

160 If the diagnosis of immune thrombocytopenic purpura is in question due to the presence of atypical f

161 Refractory immune thrombocytopenic purpura is infrequent in children, but carries substanti

162 ce and prevalence of immune thrombocytopenic purpura is limited, with nearly all data coming from Eur

163 Childhood Henoch-Schonlein purpura is more frequent in the West Midlands than previ

164 f novel therapies in immune thrombocytopenic purpura is undergoing a revolution that has the potentia

165 Adult-onset Henoch-Schonlein purpura is unusual, but through case studies, this revie

166 eatments for chronic immune thrombocytopenic purpura (ITP) act by decreasing platelet destruction.

167 erican patients with immune thrombocytopenic purpura (ITP) and the effect of H pylori eradication on

168 ytes are targeted by immune thrombocytopenic purpura (ITP) autoantibodies, as are platelets, we have

169 lt patients with idiopathic thrombocytopenic purpura (ITP) for more than 50 years.

170 sis of treatment for immune thrombocytopenic purpura (ITP) has conventionally relied on nonspecific i

171 nesis of chronic idiopathic thrombocytopenic purpura (ITP) involves antibody-mediated platelet destru

172 Idiopathic thrombocytopenic purpura (ITP) is a common hematologic disorder manifeste

173 Chronic immune thrombocytopenic purpura (ITP) is an autoimmune disease caused by platele

174 Adult chronic immune thrombocytopenic purpura (ITP) is an autoimmune disorder manifested by th

175 Chronic immune thrombocytopenic purpura (ITP) is characterised by accelerated platelet d

176 Chronic immune thrombocytopenic purpura (ITP) is characterized by low platelet counts an

177 Immune thrombocytopenic purpura (ITP) is characterized by the presence of antipl

178 Chronic immune thrombocytopenic purpura (ITP) is manifested by autoantibody-induced plat

179 Although idiopathic thrombocytopenic purpura (ITP) is the most common autoimmune hematologic

180 Patients with severe immune thrombocytopenic purpura (ITP) may require an acute increase in the plate

181 t cytopenias such as immune thrombocytopenic purpura (ITP) or autoimmune hemolytic anemia, mouse mode

182 Treatments for immune thrombocytopenic purpura (ITP) providing durable platelet responses witho

183 eatment strategy for immune thrombocytopenic purpura (ITP) through the use of a mouse model of the di

184 h recently diagnosed immune thrombocytopenic purpura (ITP) who had failed an initial steroid course t

185 diseases, including immune thrombocytopenic purpura (ITP), autoimmune neuropathies, systemic lupus e

186 ytopenia, especially immune thrombocytopenia purpura (ITP), is essential to avoid unnecessary and pot

187 ies with chronic idiopathic thrombocytopenic purpura (ITP), platelet counts less than 30 000 per muL

188 ncluded that, in idiopathic thrombocytopenic purpura (ITP), production of platelets from megakaryocyt

189 ication of childhood immune thrombocytopenia purpura (ITP).

190 eloped in a model of immune thrombocytopenic purpura (ITP).

191 80% of patients with immune thrombocytopenic purpura (ITP).

192 newly diagnosed with immune thrombocytopenic purpura (ITP).

193 t-line treatment for immune thrombocytopenic purpura (ITP).

194 95, for treatment of immune thrombocytopenic purpura (ITP).

195 tics associated with immune thrombocytopenic purpura (ITP).

196 treat patients with immune thrombocytopenic purpura (ITP).

197 ocytopenia (HIT) and immune thrombocytopenic purpura (ITP).

198 e aware of this distinctive form of necrotic purpura, its associated autoantibodies, and its link to

199 ncy and ethnic variation of Henoch-Schonlein purpura, Kawasaki disease, and rarer vasculitides during

200 eases, including thrombotic thrombocytopenic purpura, manifest much of their pathology through activa

201 A diagnosis of immune thrombocytopenic purpura may be based on an evaluation of the history, ph

202 (n = 2) and immune-mediated thrombocytopenic purpura (n = 1), were possibly related to bevacizumab.

203 IgA nephropathy and Henoch-Schonlein purpura nephritis are common glomerular disorders in ped

204 atment protocols for severe Henoch-Schonlein purpura nephritis are mentioned.

205 esis of IgA nephropathy and Henoch-Schonlein purpura nephritis has evolved over the past decade.

206 ildhood IgA nephropathy and Henoch-Schonlein purpura nephritis have the potential for serious morbidi

207 diatric IgA nephropathy and Henoch-Schonlein purpura nephritis, recent data indicate that angiotensin

208 ons in suspected thrombotic thrombocytopenic purpura, new evidence supporting the efficacy and safety

209 al mechanisms of thrombotic thrombocytopenic purpura not only provide a rationale for the previously

210 Two vaccinees presented with purpura of the lower legs; histological findings indicat

211 gement of refractory immune thrombocytopenic purpura often requires multiple agents that may provide

212 of sirolimus, the patient developed palpable purpura on the bilateral lower extremities that resolved

213 c white plaques, which may be accompanied by purpura or fissuring.

214 ascular coagulation, immune thrombocytopenic purpura, or splenic sequestration did not play a discern

215 treatment of chronic immune thrombocytopenic purpura outside a clinical trial.

216 most effective treatment of Henoch-Schonlein purpura, particularly for patients with severe nephritis

217 erature base, The Alder Hey Henoch Schonlein Purpura Pathway was developed, a revised pathway for the

218 d for idiopathic thrombotic thrombocytopenic purpura regardless of ADAMTS13 levels, but more accessib

219 thogenesis and treatment of Henoch-Schonlein purpura remains incomplete.

220 s with inherited thrombotic thrombocytopenic purpura, resulted in a significant reduction of ADAMTS13

221 diseases such as thrombotic thrombocytopenic purpura, sepsis, and diabetes among others.

222 regnant patient with immune thrombocytopenic purpura should be determined based on maternal indicatio

223 aries between types but includes arthralgia, purpura, skin ulcers, glomerulonephritis, and peripheral

224 zumab developed late immune thrombocytopenic purpura that remitted with standard therapy.

225 In thrombotic thrombocytopenic purpura, the clinical impact of ADAMTS13 deficiency caus

226 mark of IgA nephropathy and Henoch-Schonlein purpura, the onset of which often follows infections.

227 astic syndromes, idiopathic thrombocytopenic purpura, thrombocytopenia due to human immunodeficiency

228 Acquired thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are ap

229 major disorders: thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS).

230 Thrombotic thrombocytopenic purpura (TTP) and the hemolytic uremic syndrome (HUS) ar

231 cute episodes of thrombotic thrombocytopenic purpura (TTP) appears complete except for minor cognitiv

232 thic, autoimmune thrombotic thrombocytopenic purpura (TTP) by identifying naturally processed A Disin

233 thophysiology of thrombotic thrombocytopenic purpura (TTP) can be explained by the absence of active

234 Thrombotic thrombocytopenic purpura (TTP) has been a mysterious and deadly disease t

235 Thrombotic thrombocytopenic purpura (TTP) in adults is usually caused by autoantibod

236 Thrombotic thrombocytopenic purpura (TTP) is a devastating thrombotic disorder cause

237 Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease characterize

238 Immune-mediated thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder caused by a

239 Acquired thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder resulting f

240 Thrombotic thrombocytopenic purpura (TTP) is a life-threatening illness caused by de

241 Thrombotic thrombocytopenic purpura (TTP) is a life-threatening systemic illness of

242 Thrombotic thrombocytopenic purpura (TTP) is a microangiopathic disorder diagnosed b

243 Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic

244 abine-associated thrombotic thrombocytopenic purpura (TTP) is a rare complication of gemcitabine trea

245 Acquired thrombotic thrombocytopenic purpura (TTP) is caused by aggregation of platelets on u

246 Acquired thrombotic thrombocytopenic purpura (TTP) is characterized by thrombocytopenia and m

247 Thrombotic thrombocytopenic purpura (TTP) is primarily caused by immunoglobulin G (I

248 Thrombotic thrombocytopenic purpura (TTP) is the common name for adults with microan

249 Acquired thrombotic thrombocytopenic purpura (TTP) is the consequence of a severe ADAMTS13 de

250 Hereditary thrombotic thrombocytopenic purpura (TTP) may be rare, but it is forever.

251 presentations of thrombotic thrombocytopenic purpura (TTP) or heparin-induced thrombocytopenia (HIT),

252 ving protease implicated in thrombocytopenic purpura (TTP) pathogenesis was identified as ADAMTS13 (a

253 ty in congenital thrombotic thrombocytopenic purpura (TTP) patients is constrained by limitations in

254 In contrast to thrombotic thrombocytopenic purpura (TTP) patients, no aHUS patients demonstrated ul

255 HUS and acquired thrombotic thrombocytopenic purpura (TTP) remain clinical diagnoses, an increased un

256 Pathogenesis of thrombotic thrombocytopenic purpura (TTP) was a mystery for over half a century unti

257 activity causes thrombotic thrombocytopenic purpura (TTP), a life-threatening syndrome for which pla

258 pathogenesis of thrombotic thrombocytopenic purpura (TTP), a life-threatening thrombotic microangiop

259 In thrombotic thrombocytopenic purpura (TTP), a multimeric form of von Willebrand facto

260 ic treatment for thrombotic thrombocytopenic purpura (TTP), but how therapy affects the level of a di

261 cute episodes of thrombotic thrombocytopenic purpura (TTP), but pregnancy outcomes in women who have

262 tening disorder, thrombotic thrombocytopenic purpura (TTP), characterized by platelet-rich thrombi in

263 emonstrated that thrombotic thrombocytopenic purpura (TTP), characterized by widespread thrombosis in

264 transfusions in thrombotic thrombocytopenic purpura (TTP), heparin-induced thrombocytopenia (HIT) an

265 TMAs, especially thrombotic thrombocytopenic purpura (TTP), is difficult due to overlapping clinical

266 openia (ITP) and thrombotic thrombocytopenic purpura (TTP), respectively, illuminate the importance o

267 ndrome (HUS) and thrombotic thrombocytopenic purpura (TTP), the histories and presentations of which

268 In acquired thrombotic thrombocytopenic purpura (TTP), the persistence of severe ADAMTS13 defici

269 ctivity leads to thrombotic thrombocytopenic purpura (TTP).

270 of ADAMTS13 and thrombotic thrombocytopenic purpura (TTP).

271 fatal syndrome, thrombotic thrombocytopenic purpura (TTP).

272 ng of idiopathic thrombotic thrombocytopenic purpura (TTP).

273 c and HIV-linked thrombotic thrombocytopenic purpura (TTP).

274 idine-associated thrombotic thrombocytopenic purpura (TTP).

275 ts with acquired thrombotic thrombocytopenic purpura (TTP).

276 our approach to thrombotic thrombocytopenic purpura (TTP).

277 associated with thrombotic thrombocytopenic purpura (TTP).

278 protease, causes thrombotic thrombocytopenic purpura (TTP).

279 fatal syndrome, thrombotic thrombocytopenic purpura (TTP).

280 e development of thrombotic thrombocytopenic purpura (TTP).

281 can precipitate thrombotic thrombocytopenic purpura (TTP).

282 nt activation in thrombotic thrombocytopenic purpura (TTP).

283 called acquired thrombotic thrombocytopenic purpura (TTP).

284 ndrome (HUS) and thrombotic thrombocytopenic purpura (TTP).

285 e fatal disorder thrombotic thrombocytopenic purpura (TTP).

286 the symptoms of thrombotic thrombocytopenic purpura (TTP).

287 pathogenesis of thrombotic thrombocytopenic purpura (TTP).

288 g disease called thrombotic thrombocytopenic purpura (TTP).

289 s of the disease thrombotic thrombocytopenic purpura (TTP); however, experimental evidence in support

290 e United Kingdom Thrombotic Thrombocytopenic Purpura (UK TTP) Registry with clinical and laboratory d

291 timated annual incidence of Henoch-Schonlein purpura was 20.4 per 100000, and was highest between the

292 n secondary forms of immune thrombocytopenic purpura, when the hematologist plays a consultative role

293 serious underlying pathophysiology, such as purpura, which indicates a bleeding diathesis.

294 re common TMA is thrombotic thrombocytopenic purpura, which is caused by the lack of normal ADAMTS-13

295 Adults with severe thrombocytopenic purpura who responded poorly to therapeutic plasma excha

296 sk of relapse of thrombotic thrombocytopenic purpura will be important to further validate the strate

297 he various complications of Henoch-Schonlein purpura will be reviewed.

298 nts with renal disease from Henoch-Schonlein purpura will be summarized.

299 hat is associated with neutropenia, retiform purpura with cutaneous necrosis and autoantibodies consi

300 nts in patients with immune thrombocytopenic purpura, without significant adverse effects.